Is Alexion Pharmaceuticals a good stock to buy?
Is Alexion Pharmaceuticals a good stock to buy?
Alexion Pharmaceuticals has received 76.39% “outperform” votes from our community.
Is Alexion Pharmaceuticals publicly traded?
Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is an American pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases….Alexion Pharmaceuticals.
| Type | Subsidiary |
|---|---|
| Traded as | Nasdaq: ALXN |
| Industry | Pharmaceutical industry |
| Founded | 1992 |
| Founder | Leonard Bell |
How much is AstraZeneca buying Alexion for?
$39 billion
AstraZeneca is splashing out $39 billion to buy Alexion in a cash-and-stock deal, the British pharma revealed Saturday. The deal is driven by AstraZeneca’s desire to build a stronger presence in immunology—and to give its top line an immediate boost.
Will Alexion be acquired?
AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.
When did AstraZeneca acquire Alexion?
The $39bn deal, announced in December 2020, is AstraZeneca’s largest ever acquisition: allowing it to move further into immunology with an enhanced scientific presence, and giving it Alexion’s lead medicine soliris (eculizumab), among four other approved medicines and a pipeline of 11 molecules.
Who bought Alexion Pharmaceuticals?
AstraZeneca
AstraZeneca closes mega $39B Alexion buyout despite antitrust fears, making a splash in rare diseases. AstraZeneca’s mega $39 billion takeover of Alexion Pharmaceuticals has come to a close, delivering the British pharma a lucrative portfolio of immunology medicines and a towering presence in rare diseases.
What happened to Alexion Pharmaceuticals?
AstraZeneca’s mega $39 billion takeover of Alexion Pharmaceuticals has come to a close, delivering the British pharma a lucrative portfolio of immunology medicines and a towering presence in rare diseases.
Why did AstraZeneca acquired Alexion?
AstraZeneca will use the acquisition to develop a dedicated rare disease unit in Boston; while it will also speed up the worldwide expansion of the Alexion portfolio. Headquartered in Boston, Alexion will now be known as Alexion, AstraZeneca Rare Disease.
Who is buying ALXN?
U.K.-based drugmaker AstraZeneca (AZN) has agreed to buy biotech Alexion Pharmaceuticals (ALXN), a company that specializes in rare disease treatments. It’s a cash-and-stock deal valued at around $39 billion.
When did AstraZeneca buy Alexion?
Has AstraZeneca acquired Alexion?
AstraZeneca has completed its $39billion acquisition of Alexion Pharmaceuticals. The deal gives the Cambridge-headquartered biopharmaceutical company a much greater scientific presence in the fields of rare diseases and immunology.
Who owns Alexion Pharmaceuticals?
AstraZenecaAlexion Pharmaceuticals / Parent organization
https://www.youtube.com/watch?v=upiLJct3_Ik